Targeting TBL1 with tegavivint promotes anti-tumor and immunomodulatory responses in preclinical models of hepatocellular carcinoma

被引：0
|
作者：
Holloway, Kimberly R.
Drake, Thomas
Bird, Thomas
Horrigan, Stephen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6167
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6167
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma
    Drake, T.
    Tan, E. H.
    Georgakopoulou, A.
    May, S.
    Mueller, M.
    Horrigan, S.
    Holloway, K.
    Chang, J.
    Aras, R.
    Bird, T.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S19 - S19
  • [2] Osthole promotes anti-tumor immune responses in tumor-bearing mice with hepatocellular carcinoma
    Zhang, Lurong
    Jiang, Guorong
    Yao, Fei
    Liang, Guoqiang
    Wang, Fei
    Xu, Heng
    Wu, Yan
    Yu, Xiao
    Liu, Haiyan
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2015, 37 (03) : 301 - 307
  • [3] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Hung Huynh
    Richard Ong
    Khee Chee Soo
    Angiogenesis, 2012, 15 : 59 - 70
  • [4] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Huynh, Hung
    Ong, Richard
    Soo, Khee Chee
    ANGIOGENESIS, 2012, 15 (01) : 59 - 70
  • [5] Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models
    Biswas, Indrani
    Precilla, Senthilathiban Daisy
    Kumar, Aravinda
    Sekhar, M. M.
    Medasani, Renu
    Anitha, T. S.
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [6] Targeting gender specific mechanisms to enhance anti-tumor immune responses against hepatocellular carcinoma
    Barrios, Kelly
    Vidrine, Amy
    Watkins, Stephanie
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [7] A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations
    Li, Daneng
    Chen, Eric Xueyu
    Hu, Zishuo Ian
    Hsieh, David
    Hwang, Jimmy J.
    Feun, Lynn G.
    Franses, Joseph Wang
    King, Gentry Teng
    Drake, Thomas
    Suzuki, Toshiyasu
    Bird, Thomas G.
    Horrigan, Stephen
    Chang, Jean
    Stenehjem, David D.
    Cunningham, Casey
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma
    Jing Liao
    Dan-Ni Zeng
    Jin-Zhu Li
    Qiao-Min Hua
    Zhiyu Xiao
    Chuanchao He
    Kai Mao
    Ling-Yan Zhu
    Yifan Chu
    Wei-Ping Wen
    Limin Zheng
    Yan Wu
    Hepatology International, 2020, 14 : 80 - 95
  • [9] Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma
    Liao, Jing
    Zeng, Dan-Ni
    Li, Jin-Zhu
    Hua, Qiao-Min
    Xiao, Zhiyu
    He, Chuanchao
    Mao, Kai
    Zhu, Ling-Yan
    Chu, Yifan
    Wen, Wei-Ping
    Zheng, Limin
    Wu, Yan
    HEPATOLOGY INTERNATIONAL, 2020, 14 (01) : 80 - 95
  • [10] IRREVERSIBLE ELECTROPORATION INDUCES IMMUNOGENIC CELL DEATH IN HEPATOCELLULAR CARCINOMA AND PROMOTES ANTI-TUMOR IMMUNE EFFECTS IN MICE MODELS
    Liao, Junbin
    Zhang, Ning
    Xu, Lixia
    Peng, Sui
    GASTROENTEROLOGY, 2018, 154 (06) : S1155 - S1155
12345